Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients

Conditions: B-cell Acute Lymphoblastic Leukemia; Acute Lymphoblastic Leukemia, in Relapse; Refractory Acute Lymphoid Leukemia Interventions: Drug: CD19 CAR T-cell; Drug: CD22 CAR T cells; Procedure: hematopoietic stem-cell transplantation Sponsors: Beijing GoBroad Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials